SAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis — Eric Lawitz (2019) | RDL Network
SAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis
Eric Lawitz, Angie Coste, Fred Poordad, Naim Alkhouri, Nicole Loo, B. Mccolgan, Jacqueline M. Tarrant, Tuan Nguyen, Ling Han, Chuhan Chung, Adrian S. Ray, John G. McHutchison, G. Mani Subramanian, Robert P. Myers, Michael S. Middleton, Claude B. Sirlin, Rohit Loomba, Edna Nyangau, Mark Fitch, Kelvin W. Li, Marc Hellerstein
Stephen A. Harrison, Mazen Noureddin, Robert Herring, Peter Ruane, B. Mccolgan, Macky Natha, Brian J. Kirby, Cara Nelson, Raúl Antonio Aguilar Vera, Catherine Jia, Mani Subramanian, Robert P. Myers, Michael S. Middleton, Claude B. Sirlin, Mark Fitch, Kelvin W. Li, Marc Hellerstein, Eric Lawitz
S. Harrison, Mazen Noureddin, Robert Herring, P. Ruane, B. Mccolgan, Barbara D. Kirby, Christian J. Nelson, Raul Aguilar Schall, C. Jia, Madhu Subramanian, R. Myers, Mark R. Middleton, Claude B. Sirlin, Mark Fitch, K. Li, Marc Hellerstein, Eric Lawitz
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.